Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Lymphatic Diseases × cirmtuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoproliferative Disorders 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, B-Cell 1 Lymphoma 1 Lymphatic Diseases 1 Immunoproliferative Disorders 1 Immune System Diseases 1

Interventions

ibrutinib 1 cirmtuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05431179 2023-04-21

A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Oncternal Therapeutics, Inc

Phase 3 Withdrawn

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡